Submit Deal

IKARIA

Summary

Ikaria is a fully-integrated biotherapeutics company focused on developing and commercializing innovative therapeutics designed to meet the significant unmet medical needs of critically ill patients.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 1.54 B

Avg. Deal Size£ 1.54 B

Market Context

Senior Management

Daniel Tassé
CEO
Hugh O'Neill
Chairman

Sort

05 Mar 2015|United States|Biotechnology

Target: IKARIA

Bidder: MALLINCKRODT PLC

6 Service Providers

2 Target | 4 Bidder

8 Dealmakers

2 Target | 6 Bidder

£ 1.54 B

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy